{"id":"capeox-capecitabine-oxaliplatin","safety":{"commonSideEffects":[{"rate":"15-25","effect":"Hand-foot skin reaction"},{"rate":"30-40","effect":"Nausea and vomiting"},{"rate":"20-30","effect":"Diarrhea"},{"rate":"20-30","effect":"Neutropenia"},{"rate":"15-25","effect":"Peripheral neuropathy"},{"rate":"30-40","effect":"Fatigue"},{"rate":"15-20","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL414804","moleculeType":"Small molecule","molecularWeight":"395.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Capecitabine is converted to 5-fluorouracil in tumor tissue, disrupting nucleotide synthesis and DNA/RNA function. Oxaliplatin forms platinum-DNA adducts that prevent DNA replication and transcription. Together, these agents provide complementary mechanisms of action with enhanced efficacy in colorectal and other solid tumors.","oneSentence":"CapeOX combines capecitabine, a fluoropyrimidine prodrug that inhibits thymidylate synthase, with oxaliplatin, a platinum agent that forms DNA crosslinks, to provide synergistic cytotoxic activity against cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:42:24.901Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Adjuvant treatment of stage III colorectal cancer"},{"name":"Gastric cancer"},{"name":"Pancreatic cancer"}]},"trialDetails":[{"nctId":"NCT06567782","phase":"PHASE2","title":"A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-02-17","conditions":"Neoplasms, Colon","enrollment":120},{"nctId":"NCT06850103","phase":"PHASE2","title":"SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-04-22","conditions":"Colorectal Carcinoma, Oligometastases, pMMR","enrollment":51},{"nctId":"NCT07468630","phase":"PHASE2","title":"Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma","status":"RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2026-04-10","conditions":"Colon Adenocarcinoma","enrollment":106},{"nctId":"NCT07462143","phase":"PHASE2, PHASE3","title":"A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2026-04-30","conditions":"Colorectal (Colon or Rectal) Cancer","enrollment":700},{"nctId":"NCT07453875","phase":"PHASE1","title":"LDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2026-02-09","conditions":"Peritoneal Metastasis of Gastric and Colorectal Cancer, LDRT","enrollment":9},{"nctId":"NCT05731726","phase":"PHASE2","title":"Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2023-02-22","conditions":"pMMR, MSS, MSI-L","enrollment":50},{"nctId":"NCT07448142","phase":"PHASE2","title":"Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-15","conditions":"Colorectal Cancer (CRC)","enrollment":50},{"nctId":"NCT07184047","phase":"","title":"Frailty Scales for Predicting Chemotherapy Toxicity in Older Adults With Gastrointestinal Cancers","status":"COMPLETED","sponsor":"Ankara Etlik City Hospital","startDate":"2024-01-15","conditions":"Gastrointestinal Cancers, Frailty, Sarcopenia in Elderly","enrollment":72},{"nctId":"NCT07113275","phase":"PHASE3","title":"A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in High-Risk Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tao Zhang","startDate":"2026-02-11","conditions":"Rectal Cancer, Total Neoadjuvant Therapy, Radiotherapy","enrollment":435},{"nctId":"NCT06771622","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"FBD Biologics Limited","startDate":"2025-03-13","conditions":"Solid Cancer","enrollment":500},{"nctId":"NCT04854668","phase":"PHASE3","title":"A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-05-27","conditions":"Metastatic Colorectal Cancer","enrollment":748},{"nctId":"NCT06864013","phase":"PHASE2","title":"SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-01-06","conditions":"Locally Advanced Rectal Cancer (LARC)","enrollment":116},{"nctId":"NCT07284992","phase":"PHASE2","title":"SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC","status":"RECRUITING","sponsor":"Shandong Provincial Hospital","startDate":"2025-09-12","conditions":"Rectal Cancer, Advanced Stage Colorectal Cancer, Radiotherapy","enrollment":208},{"nctId":"NCT07268677","phase":"PHASE2","title":"A Single-arm Clinical Study Evaluating Pirfenidone and Sintilimab in Combination With Standard Neoadjuvant Chemotherapy for Colorectal Cancer Patients With Peritoneal Metastasis.","status":"NOT_YET_RECRUITING","sponsor":"Guoxiang Cai","startDate":"2025-12-01","conditions":"Colorectal Cancer","enrollment":30},{"nctId":"NCT07257380","phase":"PHASE2","title":"Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment: An Adaptive Trial (MRD-ATLAS)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-12-30","conditions":"Gastric / Gastroesophageal Junction Adenocarcinoma","enrollment":90},{"nctId":"NCT07239466","phase":"PHASE2","title":"A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tao Zhang","startDate":"2026-01-01","conditions":"Rectal Cancer, Radiotherapy, Immunotherapy","enrollment":48},{"nctId":"NCT06328738","phase":"PHASE1","title":"ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Enliven Therapeutics","startDate":"2024-05-30","conditions":"HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors","enrollment":275},{"nctId":"NCT03984578","phase":"PHASE2","title":"Window of Opportunity Study in Colorectal Cancer","status":"COMPLETED","sponsor":"National Cancer Centre, Singapore","startDate":"2019-06-12","conditions":"Colorectal Cancer","enrollment":33},{"nctId":"NCT04703101","phase":"PHASE1","title":"Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2021-02-11","conditions":"Locally Advanced Rectal Carcinoma, Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8","enrollment":25},{"nctId":"NCT06368141","phase":"PHASE2","title":"Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-05-01","conditions":"Colon Cancer","enrollment":56},{"nctId":"NCT06884670","phase":"PHASE2","title":"Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-03-18","conditions":"Rectal Cancer","enrollment":130},{"nctId":"NCT07007182","phase":"PHASE2","title":"Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jinbo Yue","startDate":"2025-10-01","conditions":"Gastric Adenocarcinoma, Stomach Neoplasms","enrollment":54},{"nctId":"NCT05576480","phase":"PHASE2","title":"SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2023-02-06","conditions":"Rectal Cancer, Locally Advanced","enrollment":55},{"nctId":"NCT02008656","phase":"PHASE2","title":"Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-11","conditions":"Rectal Cancer","enrollment":358},{"nctId":"NCT05515796","phase":"PHASE2","title":"Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors","status":"RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2022-09-01","conditions":"Immunotherapy, Gastric Cancer, Rectal Cancer","enrollment":200},{"nctId":"NCT00680901","phase":"PHASE3","title":"LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-06-04","conditions":"Neoplasms, Gastrointestinal Tract","enrollment":545},{"nctId":"NCT06865521","phase":"NA","title":"Akkermansia Probiotics Plus Anti-PD-1 Monoclonal Antibody in MSS/pMMR Advanced Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"West China Hospital","startDate":"2025-02-21","conditions":"Colo-rectal Cancer, PD-1 Inhibitor, Akkermansia Muciniphila","enrollment":22},{"nctId":"NCT07053150","phase":"PHASE2","title":"A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-15","conditions":"Advanced Digestive System Tumor","enrollment":80},{"nctId":"NCT04864067","phase":"PHASE2","title":"No Operation After Short Course Radiotherapy Followed By Consolidation Chemotherapy In Locally Advanced Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Servicio de Salud Metropolitano Sur Oriente","startDate":"2021-06-09","conditions":"Rectal Cancer","enrollment":73},{"nctId":"NCT06850090","phase":"PHASE3","title":"Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial","status":"NOT_YET_RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-07-30","conditions":"Rectal Cancer, Rectal Cancer Patients","enrollment":210},{"nctId":"NCT06209099","phase":"NA","title":"Organ Preservation First Strategy and Intentional Watch and Wait for MRI Defined Low-risk Rectal Cancer","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2024-01-17","conditions":"Rectal Cancer","enrollment":96},{"nctId":"NCT07007728","phase":"PHASE2","title":"Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-06-01","conditions":"Colorectal Neoplasms, Secondary Malignant Neoplasm of Liver","enrollment":54},{"nctId":"NCT04566380","phase":"PHASE2","title":"ONO-4538 Phase II Rollover Study (ONO-4538-98)","status":"RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2020-09-10","conditions":"Pan-tumor","enrollment":59},{"nctId":"NCT06157996","phase":"PHASE2","title":"Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2024-06-01","conditions":"Gastric Cancer","enrollment":92},{"nctId":"NCT06718543","phase":"PHASE2","title":"Neoadjuvant Short-Course Radiotherapy With or Without Chemotherapy and AK112 in Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"fan li","startDate":"2025-02-10","conditions":"Rectal Cancer","enrollment":100},{"nctId":"NCT06621563","phase":"PHASE1","title":"Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2024-12-14","conditions":"Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer","enrollment":780},{"nctId":"NCT06881537","phase":"PHASE2","title":"CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2024-06-01","conditions":"Locally Recurrent Colorectal Cancer","enrollment":15},{"nctId":"NCT05585814","phase":"PHASE2","title":"CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2023-05-01","conditions":"Locally Advanced Colorectal Cancer","enrollment":30},{"nctId":"NCT05216653","phase":"PHASE2","title":"Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma (PRECAM)","status":"COMPLETED","sponsor":"Sir Run Run Shaw Hospital","startDate":"2022-04-07","conditions":"MSS Locally Advanced Rectal Adenocarcinoma","enrollment":32},{"nctId":"NCT06246344","phase":"","title":"Adaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2023-12-01","conditions":"Rectal Cancer","enrollment":128},{"nctId":"NCT06835179","phase":"PHASE2","title":"SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-02","conditions":"Unresectable Metastatic Colorectal Cancer, Microsatellite Stable (MSS) Colorectal Cancer (CRC), RAS-mutant Colorectal Cancer","enrollment":28},{"nctId":"NCT06504732","phase":"PHASE2, PHASE3","title":"To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer","status":"RECRUITING","sponsor":"SUNHO（China）BioPharmaceutical CO., Ltd.","startDate":"2024-08-15","conditions":"Stomach Neoplasms, Solid Tumor","enrollment":90},{"nctId":"NCT01167725","phase":"PHASE3","title":"Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2010-08","conditions":"Colorectal Cancer","enrollment":340},{"nctId":"NCT05601505","phase":"PHASE2","title":"Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-02-03","conditions":"Locally Advanced Rectal Carcinoma, Circulating Tumor DNA","enrollment":470},{"nctId":"NCT06722950","phase":"PHASE2","title":"Phase II Clinical Study of AC591 in Preventing Oxaliplatin-Induced Peripheral Neuropathy","status":"NOT_YET_RECRUITING","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2024-12","conditions":"Colorectal Adenoma","enrollment":120},{"nctId":"NCT06709885","phase":"PHASE2","title":"HDAC Inhibitor Combination with Chemoimmunotherapy in the Neoadjuvant Treatment of PMMR Locally Advanced Colon Cancer","status":"RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2024-10-15","conditions":"Colon Adenocarcinoma","enrollment":100},{"nctId":"NCT03228043","phase":"NA","title":"Apatinib for Resectable Colorectal Cancer","status":"WITHDRAWN","sponsor":"Nanchong Central Hospital","startDate":"2020-03-01","conditions":"Apatinib, Outcome, Fatal, Colorectal Cancer","enrollment":""},{"nctId":"NCT06550453","phase":"PHASE4","title":"Safety and Efficacy of Pembrolizumab in Combination with Bevacizumab + CapeOX in the Neoadjuvant Treatment of RAS-mutated, BRAF Wild-type, Microsatellite-stabilized, Locally Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"yangjianjun","startDate":"2024-09-01","conditions":"Locally Advanced Colorectal Cancer","enrollment":20},{"nctId":"NCT06599827","phase":"PHASE2","title":"Neoadjuvant Moderately Hypofractionated Radiotherapy Combined with Chemotherapy and Immunotherapy for High-risk LARC","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-09-20","conditions":"Rectal Cancer","enrollment":54},{"nctId":"NCT06566755","phase":"PHASE3","title":"Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer","status":"RECRUITING","sponsor":"Caigang Liu","startDate":"2024-02-01","conditions":"Colorectal Cancer","enrollment":30},{"nctId":"NCT05086627","phase":"PHASE2","title":"Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2021-09-01","conditions":"Locally Advanced Rectal Cancer","enrollment":118},{"nctId":"NCT06516445","phase":"PHASE2","title":"SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC","status":"RECRUITING","sponsor":"Huazhong University of Science and Technology","startDate":"2023-06-28","conditions":"Colorectal Cancer","enrollment":33},{"nctId":"NCT06504875","phase":"","title":"Application of PD-1 Monoclonal Antibody in Combination With IL-2 and CapeOX in Organ Preservation Therapy for Ultra-Low Localized Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-07-10","conditions":"Rectal Cancer","enrollment":23},{"nctId":"NCT06504901","phase":"","title":"Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-07-10","conditions":"Colorectal Cancer","enrollment":30},{"nctId":"NCT05394740","phase":"PHASE1, PHASE2","title":"Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Center Hospital East","startDate":"2022-06-06","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma","enrollment":30},{"nctId":"NCT06455124","phase":"PHASE2","title":"Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-05-08","conditions":"Rectal Cancer","enrollment":60},{"nctId":"NCT06443671","phase":"PHASE2, PHASE3","title":"Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2024-06-01","conditions":"Rectal Cancer","enrollment":132},{"nctId":"NCT02746796","phase":"PHASE2, PHASE3","title":"Study of ONO-4538 in Gastric Cancer","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2016-03","conditions":"Gastric Cancer","enrollment":680},{"nctId":"NCT03006705","phase":"PHASE3","title":"Study of Adjuvant ONO-4538 With Resected Gastric Cancer","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2017-01-31","conditions":"Gastric Cancer","enrollment":800},{"nctId":"NCT04301557","phase":"PHASE2","title":"PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-07-31","conditions":"DMMR Colorectal Cancer, MSI-H Colorectal Cancer, Locally Advanced Colorectal Cancer","enrollment":25},{"nctId":"NCT06014372","phase":"PHASE2","title":"Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-07-01","conditions":"Colon Cancer, Neoadjuvant Therapy, Immunotherapy","enrollment":55},{"nctId":"NCT06202716","phase":"PHASE2","title":"Cadonilimab Plus CapeOX as First-Line Treatment for Advanced GC/GEJC With High TMEscore","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2024-04","conditions":"Gastric Cancer","enrollment":50},{"nctId":"NCT04249739","phase":"PHASE2","title":"Pembrolizumab + Capecitabine／Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive","status":"ACTIVE_NOT_RECRUITING","sponsor":"Samsung Medical Center","startDate":"2020-09-29","conditions":"Gastric Cancer","enrollment":93},{"nctId":"NCT06266832","phase":"PHASE2","title":"The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma","status":"RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2024-01-01","conditions":"Rectal Adenocarcinoma","enrollment":30},{"nctId":"NCT06235164","phase":"","title":"The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer","status":"UNKNOWN","sponsor":"Fujian Medical University","startDate":"2019-01-01","conditions":"Locally Advanced Gastric Cancer","enrollment":585},{"nctId":"NCT06204484","phase":"NA","title":"MRD-guided Deferred Adjuvant Therapy in Resectable Early-stage Colon Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-07-26","conditions":"Colorectal Cancer","enrollment":349},{"nctId":"NCT03840239","phase":"PHASE2","title":"TNT to Increase the Clinical Complete Response Rate for Distal LARC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2018-12-25","conditions":"Rectal Cancer, Rectal Cancer Stage II, Rectal Cancer Stage III","enrollment":98},{"nctId":"NCT05307198","phase":"PHASE2","title":"Rectal Artery Infusion Chemotherapy Combined With Anti-PD1 Antibody for MSS LARC","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-05-11","conditions":"Rectal Neoplasms","enrollment":38},{"nctId":"NCT06035133","phase":"NA","title":"Treatment of Low Locally Advanced Rectal Cancer With Radiotherapy Removal TNT Plus Neoadjuvant Therapy","status":"NOT_YET_RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2023-11-10","conditions":"Rectal Cancer","enrollment":213},{"nctId":"NCT05998122","phase":"PHASE2","title":"Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study","status":"NOT_YET_RECRUITING","sponsor":"The First Hospital of Jilin University","startDate":"2023-09-01","conditions":"Locally Advanced Rectal Cancer, Total Neoadjuvant Treatment, Anti-PD-1","enrollment":45},{"nctId":"NCT05974059","phase":"PHASE2","title":"Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-08-01","conditions":"Locally Advanced Unresectable Gastric Adenocarcinoma","enrollment":20},{"nctId":"NCT05832398","phase":"NA","title":"Precision Chemotherapy Based on Organoid Drug Sensitivity for Colorectal Cancer","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2023-05-01","conditions":"Colorectal Cancer","enrollment":186},{"nctId":"NCT05797467","phase":"PHASE3","title":"Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2023-04-01","conditions":"Colorectal Cancer, Chemotherapy Effect","enrollment":366},{"nctId":"NCT05640609","phase":"PHASE1, PHASE2","title":"Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2023-03-10","conditions":"Stomach Neoplasm","enrollment":57},{"nctId":"NCT05858567","phase":"PHASE2","title":"Total Neoadjuvant Therapy With Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Ultra Low Rectal Adenocarcinoma","status":"UNKNOWN","sponsor":"Sir Run Run Shaw Hospital","startDate":"2023-05-11","conditions":"Rectal Cancer","enrollment":30},{"nctId":"NCT05752136","phase":"PHASE3","title":"Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma","status":"RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2023-04-01","conditions":"Rectal Cancer","enrollment":108},{"nctId":"NCT05815082","phase":"PHASE3","title":"ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2023-02-20","conditions":"Colorectal Cancer, Liver Metastases, Circulating Tumor Cell","enrollment":490},{"nctId":"NCT05797077","phase":"PHASE3","title":"Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2023-02-20","conditions":"Colorectal Cancer, Liver Metastases, Circulating Tumor Cell","enrollment":346},{"nctId":"NCT05742620","phase":"NA","title":"Adjuvant Treatment of Digestive Tract Tumors","status":"NOT_YET_RECRUITING","sponsor":"Xijing Hospital","startDate":"2023-06-20","conditions":"Adjuvant Treatment","enrollment":100},{"nctId":"NCT05202314","phase":"NA","title":"Camrelizumab Combined With Neoadjuvant Chemotherapy After Stent Placement for Left-Sided Obstructive Colonic Cancer","status":"RECRUITING","sponsor":"Beijing Chao Yang Hospital","startDate":"2021-12-12","conditions":"Colorectal Cancer, Neoadjuvant Chemotherapy, Stent","enrollment":20},{"nctId":"NCT04304209","phase":"PHASE2","title":"Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2019-10-28","conditions":"Colorectal Cancer Stage II, Colorectal Cancer Stage III","enrollment":195},{"nctId":"NCT05699746","phase":"PHASE3","title":"CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang University","startDate":"2023-03","conditions":"Colorectal Cancer","enrollment":38},{"nctId":"NCT05279612","phase":"","title":"Effect Analysis of Neoadjuvant Chemoradiotherapy Combined With Surgery in Laparoscope for Advanced Colon Cancer","status":"UNKNOWN","sponsor":"Tang-Du Hospital","startDate":"2021-10-01","conditions":"Colon Neoplasm","enrollment":177},{"nctId":"NCT05359393","phase":"PHASE2","title":"A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2022-12-01","conditions":"Advanced Rectal Cancer, Liver Metastasis, Pulmonary Metastasis","enrollment":52},{"nctId":"NCT04080843","phase":"PHASE2","title":"Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2019-11-15","conditions":"Colorectal Cancer, RAS and BRAF Wild-type, Colorectal Neoplasms","enrollment":30},{"nctId":"NCT05438108","phase":"PHASE2","title":"SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab in First-line Treatment of mCRC","status":"UNKNOWN","sponsor":"Huazhong University of Science and Technology","startDate":"2022-07-01","conditions":"Metastatic Colorectal Cancer","enrollment":30},{"nctId":"NCT02121405","phase":"PHASE3","title":"Randomized Trial of Primary Surgery Followed Selective Radiochemotherapy for Rectal Cancer With MRI Negative CRM","status":"SUSPENDED","sponsor":"Zhejiang University","startDate":"2015-10","conditions":"Colorectal Neoplasm, Effects of Radiation Therapy, Effects of Chemotherapy","enrollment":350},{"nctId":"NCT05201430","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2021-08-27","conditions":"Rectal Cancer","enrollment":300},{"nctId":"NCT05200299","phase":"PHASE2","title":"mFOLFOXIRI Compared to mFOLFOX6 or CapeOx as Adjuvant Chemotherapy for Stage IIIB or IIIC Colorectal Cancer","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2022-02-01","conditions":"Colorectal Cancer","enrollment":100},{"nctId":"NCT05194878","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-12-01","conditions":"Colon Cancer Stage II, Colon Cancer Stage III","enrollment":840},{"nctId":"NCT05068206","phase":"PHASE2","title":"A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-10-08","conditions":"Unresectable Metastatic Colorectal Cancer","enrollment":120},{"nctId":"NCT04997837","phase":"PHASE3","title":"Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2021-07-21","conditions":"Gastric Cancer","enrollment":433},{"nctId":"NCT02860234","phase":"","title":"Tailored Operative or Non-operative Management for Low-risk Rectal Cancer After Intensive Neoadjuvant Treatment","status":"COMPLETED","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2016-08","conditions":"Rectal Cancer","enrollment":68},{"nctId":"NCT02864849","phase":"PHASE2","title":"Total Neoadjuvant Induction and Consolidation CapeOX Plus IMRT With Capecitabine for MRI Defined High-risk Rectal Cancer","status":"COMPLETED","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2016-08","conditions":"Rectal Cancer","enrollment":81},{"nctId":"NCT01280643","phase":"NA","title":"Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Fox Chase Cancer Center","startDate":"2010-03","conditions":"Metastatic Colorectal Cancer","enrollment":3},{"nctId":"NCT02972541","phase":"NA","title":"Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer","status":"UNKNOWN","sponsor":"Beijing Chao Yang Hospital","startDate":"2016-09-30","conditions":"Colorectal Cancer, Neoadjuvant Chemotherapy, Stent","enrollment":248},{"nctId":"NCT03031444","phase":"PHASE2, PHASE3","title":"Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis","status":"COMPLETED","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2016-01","conditions":"Colorectal Cancer Stage IV, Metastasis","enrollment":135},{"nctId":"NCT04405206","phase":"","title":"Total Neoadjuvant Therapy Followed by 'Watch and Wait' Approach or Organ Preservation for Low-risk Rectal Cancer","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2020-05-25","conditions":"Rectum Cancer","enrollment":54},{"nctId":"NCT03515941","phase":"EARLY_PHASE1","title":"Postoperative Chemoradiation or Chemotherapy After Preoperative Chemotherapy for Gastric Cancers","status":"TERMINATED","sponsor":"Tannaz Armaghany","startDate":"2018-06-22","conditions":"Gastrointestinal Cancer","enrollment":6},{"nctId":"NCT04340401","phase":"PHASE2","title":"Total Neoadjuvant Treatment Plus SHR1210 for High-risk Rectal Cancer and Biomarker Screening Base on Neoantigen","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2020-05-25","conditions":"Rectal Cancer","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CapeOX（Capecitabine+Oxaliplatin）","genericName":"CapeOX（Capecitabine+Oxaliplatin）","companyName":"Peking University Cancer Hospital & Institute","companyId":"peking-university-cancer-hospital-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CapeOX combines capecitabine, a fluoropyrimidine prodrug that inhibits thymidylate synthase, with oxaliplatin, a platinum agent that forms DNA crosslinks, to provide synergistic cytotoxic activity against cancer cells. Used for Metastatic colorectal cancer, Adjuvant treatment of stage III colorectal cancer, Gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}